Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 5/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7829947 | 1.00 | LMNA (0.67) | LMNAHTTSMN1; SMN2ALOX15HPGD | |
| SCHEMBL12046948 | 0.99 | LMNA (0.68) | LMNAHTTSMN1; SMN2ALOX15HPGD | |
| SCHEMBL12046962 | 0.94 | LMNA (0.74) | LMNAHTTSMN1; SMN2ALOX15HPGD | |
| SCHEMBL7382460 | 0.89 | HPGD (0.65) | LMNAHTTSMN1; SMN2ALOX15HPGD | |
| SCHEMBL4700801 | 0.85 | HTT (0.69) | LMNAHTTSMN1; SMN2ALOX15HPGD | |
| SCHEMBL7835431 | 0.85 | SMN1; SMN2 (0.89) | LMNAHTTSMN1; SMN2ALOX15HPGD | |
| SCHEMBL7835167 | 0.85 | SMN1; SMN2 (0.89) | LMNAHTTSMN1; SMN2ALOX15HPGD | |
| Methane SCHEMBL7997331 | 0.83 | SMN1; SMN2 (0.86) | LMNAHTTSMN1; SMN2ALOX15HPGD | |
| SCHEMBL4703104 | 0.83 | HTT (0.71) | LMNAHTTSMN1; SMN2ALOX15HPGD | |
| SCHEMBL6645560 | 0.83 | SMN1; SMN2 (0.91) | LMNAHTTSMN1; SMN2ALOX15HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071620-B2 | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-8071620-B2 | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-20100093743-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093743-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-7652036-B2 | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2010-01-26 | — | — | US | disclosed |
| US-7652036-B2 | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2010-01-26 | — | — | US | disclosed |
| EP-0737671-B1 | Aromatic hydroxamic acid compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-12-12 | — | — | EP | disclosed |
| US-5804601-A | USEFUL FOR TREATING ALZHEIMER'S DISEASE, MULTIPLE SCLEROSIS, BACTERIAL OR VIRAL MENINGITIS, DOWN'S SYNDROME AND PARKINSON'S DISEASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-09-08 | — | — | US | disclosed |
| EP-0737671-A2 | Aromatic hydroxamic acid compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1996-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093743-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | HDAC1, HDAC7, HDAC5 | LMNA 364/4885HTT 1234/4885SMN1; SMN2 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.